Ronald Bugaoan, MD
Psychiatry · Hanover, MANPI 1861551236
Payments from drug & device makers
Across 259 payments — averaging $137.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$22K
- Indivior Inc.$11K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$338
- E.r. Squibb & Sons, L.L.C.$279
- Axsome Therapeutics, Inc.$264
- plus $937 from 12 others
What the payments were for
- Speaking & faculty fees$28,02079%
- Travel & lodging$2,0516%
- Food & beverage$5,48915%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 77 | $21,986 |
| Indivior Inc. | 47 | $10,654 |
| AbbVie(2 entities) | 62 | $1,133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $338 |
| E.r. Squibb & Sons, L.L.C. | 5 | $279 |
| Axsome Therapeutics, Inc. | 8 | $264 |
| Lundbeck LLC | 8 | $192 |
| Vanda Pharmaceuticals Inc. | 8 | $183 |
| Corium, LLC | 7 | $171 |
| Braeburn Inc. | 6 | $101 |
| Sunovion Pharmaceuticals Inc. | 5 | $83 |
| Bausch Health US, LLC | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Tempus AI, Inc | 2 | $36 |
| Masimo Corporation | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,590 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 11 | $16,923 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 79 | $7,591 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $6,383 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $793 |
| Quetiapine Fumarate | 38 | $736 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 38 | $718 |
| Lorazepam | 54 | $456 |
| Methylphenidate Hcl | 34 | $438 |
| Duloxetine Hcl | 25 | $435 |
| Buspirone Hcl | 16 | $346 |
| Sertraline Hcl | 22 | $336 |
| Lamotrigine | 15 | $320 |
| Bupropion Hcl SrBupropion Hcl | 12 | $276 |
| Propranolol Hcl | 11 | $275 |
| Fluoxetine Hcl | 28 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $21,986 | $16,92311 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $22 | $7,59179 claims |
| Indivior Inc.Suboxone | $10,654 | $6,38314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Hanover
- Lee CohenBoston$7M
- Dyanna DomiliciBoston$5.8M
- Arkadiy StolyarBelmont$3.3M
- Maurizio FavaBoston$2.8M
- Marc ShayAmesbury$1.7M
- Martha StarkNewton$1.6M
- Hadine JoffeBoston$1.5M
- Malini NairWinchester$1M
- Xiaoduo FanWorcester$950K
- Anthony RothschildWorcester$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.